Detection of natural resistance-associated substitutions by ion semiconductor technology in HCV1b positive, direct-acting antiviral agents-naïve patients

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Marascio, Nadia ^a,b   Pavia, Grazia ^a   Strazzulla, Alessio ^a   Dierckx, Tim ^b   Cuypers, Lize ^b   Vrancken, Bram ^b   Barreca, Giorgio Settimo ^a   Mirante, Teresa ^a   Malanga, Donatella ^a   Oliveira, Duarte Mendes ^a   Vandamme, Anne Mieke ^b,c   Torti, Carlo ^a   Liberto, Maria Carla ^a   Focà, Alfredo ^a   Giancotti, Aida ^a   Zicca, Emilia ^a   Costa, Chiara ^a   Pisani, Vincenzo ^a   Postorino, Maria Concetta ^a   Mazzitelli, Maria ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Deep sequencing; Direct acting antiviral agents; Hepatitis C virus 1b; Resistance associated substitutions

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DASABUVIR; GRAZOPREVIR; PARITAPREVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; VIRAL PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COHABITATION; CONSENSUS SEQUENCE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; ION SEMICONDUCTOR TECHNOLOGY; LIVER FIBROSIS; MALE; MIDDLE AGED; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; RESISTANCE ASSOCIATED SUBSTITUTION; SEMICONDUCTOR; SEQUENCE ANALYSIS; SURGERY; TATTOO; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS CHARACTERIZATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; MUTATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; OLIGOPEPTIDES; PROLINE; SIMEPREVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84984823864     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091416     Document Type: Article

References (59)

1. European Association for the Study of the Liver. EASL recommendation on treatment of hepatitis C 2015. J. Hepatol. 2015, 63, 199-236.
2. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358, 958-965
3. Feeney, E.R.; Chung, R.T. Antiviral treatment of hepatitis C. BMJ 2014
4. Asselah, T.; Boyer, N.; Saadoun, D.; Martinot-Peignoux, M.; Marcellin, P. Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives. Liver Int. 2016, 36, 47-57
5. Lontok, E.; Harrington, P.; Howe, A.; Kieffer, T.; Lennerstrand, J.; Lenz, O.; McPhee, F.; Mo, H.; Parkin, N.; Pilot-Matias, T.; Miller, V. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 2015, 61, 1623-1632
6. Ahmed, A.; Felmlee, D.J. Mechanisms of hepatitis c viral resistance to direct acting antivirals. Viruses 2015, 7, 6716-6729
7. Cento, V.; Chevaliez, S.; Perno, C.F. Resistance to direct-acting antiviral agents: Clinical utility and significance. Curr. Opin. HIV AIDS 2015, 10, 381-389
8. Cuypers, L.; Ceccherini Silberstein, F.; Van Laethem, K.; Li, G.; Vandamme, A.M.; Rockstroh, J.K. Impact of HCV genotype on treatment regimens and drug resistance: A snapshot in time. Rev. Med. Virol. 2016
9. Chen, Z.; Li, H.; Ren, H.; Hu, P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data. Sci. Rep. 2016, 6, 20310-20319
10. Guelfo, J.R.; Macias, J.; Neukam, K.; di Lello, F.A.; Mira, J.A.; Merchante, N.; Mancebo, M.; Nunez-Torres, R.; Pineda, J.A.; Real, L.M. Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: Implications for direct-acting antiviral treatment. J. Clin. Microbiol. 2014, 52, 4027-4029
11. Richter, S.S. Laboratory assays for diagnosis and management of hepatitis C virus infection. J. Clin. Microbiol. 2002, 40, 4407-4412
12. Simmonds, P. The origin of hepatitis C virus. Curr. Top. Microbiol. Immunol. 2013, 369, 1-15.
13. Tong, Y.Q.; Liu, B.; Liu, H.; Zheng, H.Y.; Gu, J.; Liu, H.; Song, E.J.; Song, C.; Li, Y. Accurate genotyping of hepatitis C virus through nucleotide sequencing and identification of new HCV subtypes in China population. Clin. Microbiol. Infect. 2015, 21, 9-21
14. Di Maio, V.C.; Cento, V.; di Paolo, D.; Aragri, M.; De Leonardis, F.; Tontodonati, M.; Micheli, V.; Bellocchi, M.C.; Antonucci, F.P.; Bertoli, A.; et al. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J. Antimicrob. Chemother. 2016, 71, 739-750
15. Smith, D.B.; Bukh, J.; Kuiken, C.; Muerhoff, A.S.; Rice, C.M.; Stapleton, J.T.; Simmonds, P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 2014, 59, 318-327
16. Bergfors, A.; Leenheer, D.; Bergqvist, A.; Ameur, A.; Lennerstrand, J. Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing. Antivir. Res. 2016, 126, 81-89
17. Vrancken, B.; Lequime, S.; Theys, K.; Lemey, P. Covering all bases in HIV research: unveiling a hidden world of viral evolution. AIDS Rev. 2010, 12, 89-102.
18. Zhao, Q.; Wen, Y.; Jiang, Y.; Zhang, C.; Li, Y.; Zhang, G.; Zhang, L.; Qiu, M. Next generation sequencing-based investigation of potential patient-to-patient hepatitis C virus transmission during hemodialytic treatment. PLoS ONE 2016, 11, e0147566
19. Ogishi, M.; Yotsuyanagi, H.; Tsutsumi, T.; Gatanaga, H.; Ode, H.; Sugiura, W.; Moriya, K.; Oka, S.; Kimura, S.; Koike, K. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: Comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. PLoS ONE 2015, 10, e0119145
20. Barzon, L.; Lavezzo, E.; Militello, V.; Toppo, S.; Palu, G. Applications of next-generation sequencing technologies to diagnostic virology. Int. J. Mol. Sci. 2011, 12, 7861-7884
21. Brister, J.R.; Ako-Adjei, D.; Bao, Y.; Blinkova, O. NCBI Viral Genomes Resource. Nucleic Acids Res. 2014, 43, 571-577
22. Capobianchi, M.R.; Giombini, E.; Rozera, G. Next-generation sequencing technology in clinical virology. Clin. Microbiol. Infect. 2013, 19, 15-22
23. Poon, A.F.; Swenson, L.C.; Dong, W.W.; Deng, W.; Kosakovsky Pond, S.L.; Brumme, Z.L.; Mullins, J.I.; Richman, D.D.; Harrigan, P.R.; Frost, S.D. Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol. Biol. Evol. 2010, 27, 819-832
24. Zagordi, O.; Däumer, M.; Beisel, C.; Beerenwinkel, N. Read length versus depth of coverage for viral quasispecies reconstruction. PLoS ONE 2012, 7, e47046
25. Chang, M.W.; Oliveira, G.; Yuan, J.; Okulicz, J.F.; Levy, S.; Torbett, B.E. Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. J. Virol. Methods 2013, 189, 232-234
26. Akuta, N.; Suzuki, F.; Seko, Y.; Kawamura, Y.; Sezaki, H.; Suzuki, Y.; Hosaka, T.; Kobayashi, M.; Hara, T.; Kobayashi, M.; et al. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J. Med. Virol. 2013, 85, 1028-1036
27. Gibson, R.M.; Weber, J.; Winner, D.; Miller, M.D.; Quinones-Mateu, M.E. Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy. PLoS ONE 2014, 9, e104512
28. Akuta, N.; Suzuki, F.; Fukushima, T.; Kawamura, Y.; Sezaki, H.; Suzuki, Y.; Hosaka, T.; Kobayashi, M.; Hara, T.; Kobayashi, M.; et al. Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J. Clin. Microbiol. 2014, 52, 193-200
29. Hoffmann, L.; Faffe, D.S.; Lima, J.F.C.; Capitanio, T.A.; Cabral, B.C.A.; Urmenyi, T.P.; Coelho, H.S.; Rondinelli, E.; Villela-Nogueira, C.A.; Silva, R. No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy. BBA Clin. 2015, 3, 146-151
30. Joshi, N.A.; Fass, J.N. Sickle: A sliding-window, adaptive, quality-based trimming tool for FastQ files (Version 1.33). Available online: http://www.oalib.com/references/15483271 (accessed on 1 June 2016).
31. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 2011, 17, 10-12
32. Marinier, E.; Brown, D.G.; McConkey, B.J. Pollux: Platform independent error correction of single and mixed genomes. BMC Bioinform. 2015
33. Yang, X.; Charlebois, P.; Gnerre, S.; Coole, M.G.; Lennon, N.J.; Levin, J.Z.; Qu, J.; Ryan, E.M.; Zody, M.C.; Henn, M.R. De novo assembly of highly diverse viral populations. BMC Genomics 2012, 13, 475
34. Charlebois, P.; Yang, X.; Newman, R.M.; Henn, M.R.; Zody, M.C. V-FAT: A post-assembly pipeline for the finishing and annotation of viral genomes. Available online: http://www.broadinstitute.org/scientific-community/science/projects/viral-genomics/v-fat (accessed on 1 June 2016).
35. Castera, L.; Vergniol, J.; Foucher, J.; Le Bail, B.; Chanteloup, E.; Haaser, M.; Darriet, M.; Couzigou, P.; de Ledinghen, V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128, 343-350
36. Howe, A.Y.; Black, S.; Curry, S.; Ludmerer, S.W.; Liu, R.; Barnard, R.J.; Newhard, W.; Hwang, P.M.; Nickle, D.; Gilbert, C. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin. Infect. Dis. 2014, 59, 1657-1665
37. Zeuzem, S.; Ghalib, R.; Reddy, K.R.; Pockros, P.J.; Ben Ari, Z.; Zhao, Y.; Brown, D.D.; Wan, S.; di Nubile, M.J.; Nguyen, B.Y. Grazoprevir-Elbasvir Combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann. Intern. Med. 2015, 163, 1-13
38. Di Maio, V.C.; Cento, V.; Mirabelli, C.; Artese, A.; Costa, G.; Alcaro, S.; Perno, C.F.; Ceccherini-Silberstein, F. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob. Agents Chemother. 2014, 58, 2781-2797
39. Cuypers, L.; Snoeck, J.; Vrancken, B.; Kerremans, L.; Vuagniaux, G.; Verbeeck, J.; Nevens, F.; Camacho, R.J.; Vandamme, A.M.; Van Dooren, S. A near-full length genotypic assay for HCV1b. J. Virol. Methods 2014, 209, 126-135
40. th European Meeting on HIV & Hepatitis-Treatment Strategies & Antiviral Drug Resistance, Rome, Italy, May 2016.
41. Vrancken, B.; Trovao, N.S.; Baele, G.; van Wijngaerden, E.; Vandamme, A.M.; van Laethem, K.; Lemey, P. Quantifying next generation sequencing sample pre-processing bias in HIV-1 complete genome sequencing. Viruses 2016, 8, 12-26
42. Mantry, P.S.; Pathak, L. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: A new face of cure, an expert review. Expert Rev. Anti Infect. Ther. 2016, 14, 157-165
43. Ciccozzi, M.; Equestre, M.; Costantino, A.; Marascio, N.; Quirino, A.; Lo Presti, A.; Cella, E.; Bruni, R.; Liberto, M.C.; Foca, A.; et al. Hepatitis C virus genotype 4d in Southern Italy: Reconstruction of its origin and spread by a phylodynamic analysis. J. Med. Virol. 2012, 84, 1613-1619
44. Marascio, N.; Ciccozzi, M.; Equestre, M.; Lo Presti, A.; Costantino, A.; Cella, E.; Bruni, R.; Liberto, M.C.; Pisani, G.; Zicca, E.; et al. Back to the origin of HCV2c subtype and spreading to the Calabria region (Southern Italy) over the last two centuries: A phylogenetic study. Infect. Genet. Evol. 2014, 26, 352-358
45. Sullivan, J.C.; De Meyer, S.; Bartels, D.J.; Dierynck, I.; Zhang, E.Z.; Spanks, J.; Tigges, A.M.; Ghys, A.; Dorrian, J.; Adda, N.; et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 2013, 57, 221-229
46. Cuypers, L.; Li, G.; Libin, P.; Piampongsant, S.; Vandamme, A.M.; Theys, K. Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: Significance for direct-acting antiviral treatment and drug resistance. Viruses 2015, 7, 5018-5039
47. Clavel, F.; Hance, A.J. HIV drug resistance. N. Engl. J. Med. 2004, 350, 1023-1035
48. Torti, C.; Zazzi, M.; Abenavoli, L.; Trapasso, F.; Cesario, F.; Corigliano, D.; Cosco, L.; Costa, C.; Curia, R.L.; De Rosa, M.; et al. Future research and collaboration: The "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). BMC Infect. Dis. 2012
49. Rothberg, J.M.; Hinz, W.; Rearick, T.M.; Schultz, J.; Mileski, W.; Davey, M.; Leamon, J.H.; Johnson, K.; Milgrew, M.J.; Edwards, M.; et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011, 475, 348-352
50. Yang, X.; Charlebois, P.; Macalalad, A.; Henn, M.R.; Zody, M.C. V-Phaser 2: Variant inference for viral populations. BMC Genom. 2013
51. De Oliveira, T.; Deforche, K.; Cassol, S.; Salminen, M.; Paraskevis, D.; Seebregts, C.; Snoeck, J.; van Rensburg, E.J.; Wensing, A.M.; van de Vijver, D.A.; et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005, 21, 3797-3800
52. Struck, D.; Lawyer, G.; Ternes, A.M.; Schmit, J.C.; Bercoff, D.P. COMET: Adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014
53. Kuiken, C.; Hraber, P.; Thurmond, J.; Yusim, K. The hepatitis C sequence database in Los Alamos. Nucleic Acids Res. 2008, 36, 512-516
54. Thompson, J.D.; Higgins, D.G.; Gibson, T.J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680
55. Tamura, K.; Peterson, D.; Peterson, N.; Stecher, G.; Nei, M.; Kumar, S. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28, 2731-2739
56. Stamatakis, A. RAxML-VI-HPC: Maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 2006, 22, 2688-2690
57. Kalaghatgi, P.; Sikorski, A.M.; Knops, E.; Rupp, D.; Sierra, S.; Heger, E.; Neumann-Fraune, M.; Beggel, B.; Walker, A.; Timm, J.; Walter, H.; et al. Geno2pheno[HCV]-A web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS ONE 2016, 11, e0155869
58. Edgar, R.C. MUSCLE: A multiple sequence alignment method with reduced time and space complexity. BMC Bioinform. 2004, 5, 113-132
59. Benson, D.A.; Clark, K.; Karsch-Mizrachi, I.; Lipman, D.J.; Ostell, J.; Sayers, E.W. GenBank. Nucleic Acids Res. 2014, 42, 32-37